



**University of  
Zurich<sup>UZH</sup>**

**Zurich Open Repository and  
Archive**

University of Zurich  
University Library  
Strickhofstrasse 39  
CH-8057 Zurich  
[www.zora.uzh.ch](http://www.zora.uzh.ch)

---

Year: 2013

---

**Antiretroviral drug-related liver mortality among HIV-positive persons in the absence of HBV or HCV co-infection. The Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Study**

Kovari, Helen ; Sabin, Caroline A ; Ledergerber, Bruno ; Ryom, Lene ; Worm, Signe W ; Smith, Colette ; Phillips, Andrew ; Reiss, Peter ; Fontas, Eric ; Petoumenos, Kathy ; De Wit, Stéphane ; Morlat, Philippe ; Lundgren, Jens D ; Weber, Rainer

**Abstract:** Background. Liver diseases are leading causes of death in HIV-positive persons since the widespread use of combination antiretroviral treatment (ART). Most of these deaths are due to hepatitis C (HCV) or B (HBV) virus co-infections. Little is known about other causes. Prolonged exposure to some antiretroviral drugs might increase hepatic mortality. Methods. All patients of the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study without HCV or HBV co-infection were prospectively followed from date of entry until death, or last follow-up. In patients with liver-related death, clinical charts were reviewed using a structured questionnaire. Results. We followed 22,910 participants without hepatitis virus co-infection for 114,478 person-years. There were 12 liver-related deaths (incidence, 0.10/1000 person-years); 7 because of severe alcohol use and 5 due to established ART-related toxicity. The rate of ART-related deaths in treatment-experienced persons was 0.04 (95% CI 0.01, 0.10) per 1000 person-years. Conclusions. We found a low incidence of liver-related deaths in HIV-infected persons without HCV or HBV co-infection. Liver-related mortality because of ART-related toxicity was rare.

DOI: <https://doi.org/10.1093/cid/cis919>

Posted at the Zurich Open Repository and Archive, University of Zurich

ZORA URL: <https://doi.org/10.5167/uzh-67845>

Journal Article

Accepted Version

Originally published at:

Kovari, Helen; Sabin, Caroline A; Ledergerber, Bruno; Ryom, Lene; Worm, Signe W; Smith, Colette; Phillips, Andrew; Reiss, Peter; Fontas, Eric; Petoumenos, Kathy; De Wit, Stéphane; Morlat, Philippe; Lundgren, Jens D; Weber, Rainer (2013). Antiretroviral drug-related liver mortality among HIV-positive persons in the absence of HBV or HCV co-infection. The Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Study. *Clinical Infectious Diseases*, 56(6):870-879.

DOI: <https://doi.org/10.1093/cid/cis919>

**Antiretroviral drug-related liver mortality among HIV-positive persons in the absence of HBV or HCV co-infection. The Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Study**

**Helen Kovari<sup>1</sup>, Caroline A. Sabin<sup>2</sup>, Bruno Ledergerber<sup>1</sup>, Lene Ryom<sup>3</sup>, Signe W. Worm<sup>3</sup>, Colette Smith<sup>2</sup>, Andrew Phillips<sup>2</sup>, Peter Reiss<sup>4</sup>, Eric Fontas<sup>5</sup>, Kathy Petoumenos<sup>6</sup>, Stéphane De Wit<sup>7</sup>, Philippe Morlat<sup>8</sup>, Jens D. Lundgren<sup>3</sup>, Rainer Weber<sup>1</sup>**

<sup>1</sup>Division of Infectious Diseases and Hospital Epidemiology, University Hospital, Zurich, University of Zurich, Switzerland

<sup>2</sup>Research Department of Infection and Population Health, Division of Population Health, Royal Free and University College, London, UK

<sup>3</sup>Copenhagen HIV Programme, University of Copenhagen, Copenhagen, Denmark

<sup>4</sup>HIV Monitoring Foundation, Academic Medical Center, Amsterdam, the Netherlands

<sup>5</sup>Département de santé publique, Centre Hospitalier Universitaire, Nice, France

<sup>6</sup>National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, Sydney, Australia

<sup>7</sup>Department of Infectious Diseases, St Pierre University Hospital, Brussels

<sup>8</sup>Service de médecine interne et maladies infectieuses, Hôpital Saint-André, CHU de Bordeaux, Bordeaux, France

Correspondence: Helen Kovari, M.D. Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, CH-8091 Zurich, Switzerland, Tel +41 44 255 91 95 or +41 44 255 11 11, Fax +41 44 255 32 91, Email: helen.kovari@usz.ch

Alternative address: Rainer Weber, M.D. Division of Infectious Diseases and Hospital  
Epidemiology, University Hospital Zurich, CH-8091 Zurich, Switzerland, Tel +41-44-255  
25 41 or +41-44-255 11 11, Fax +41 44 255 32 91, Email: rainer.weber@usz.ch

summary:

In a large prospective multicohort study 22,910 HIV-positive participants without HBV  
or HCV co-infection were followed for 114,478 patient-years. The incidence of liver-  
related death was low at 0.10 per 1000 patient-years. Liver-related mortality due to  
antiretroviral drug-related toxicity was rare.

## ABSTRACT

**Background:** Liver diseases are leading causes of death in HIV-positive persons since the widespread use of combination antiretroviral treatment (ART). Most of these deaths are due to hepatitis C (HCV) or B (HBV) virus co-infections. Little is known about other causes. Prolonged exposure to some antiretroviral drugs might increase hepatic mortality.

**Methods:** All patients of the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study without HCV or HBV co-infection were prospectively followed from date of entry until death, or last follow-up. In patients with liver-related death, clinical charts were reviewed using a structured questionnaire.

**Results:** We followed 22,910 participants without hepatitis virus co-infection for 114,478 person-years. There were 12 liver-related deaths (incidence, 0.10/1000 person-years); 7 because of severe alcohol use and 5 due to established ART-related toxicity. The rate of ART-related deaths in treatment-experienced persons was 0.04 (95% CI 0.01, 0.10) per 1000 person-years.

**Conclusions:** We found a low incidence of liver-related deaths in HIV-infected persons without HCV or HBV co-infection. Liver-related mortality because of ART-related toxicity was rare.

## INTRODUCTION

Liver diseases are among the most frequent causes of non-AIDS-related deaths in HIV-positive persons [1-4]. Most of these deaths are the consequence of hepatitis C (HCV) or hepatitis B virus (HBV) co-infections, or alcohol use; little is known about other causes [5]. Results of two prospective observational cohorts suggest that prolonged exposure to antiretroviral therapy (ART) may increase the risk for fatal liver failure. The Data Collection on Adverse Events of Anti-HIV Drug (D:A:D) cohort, including many HCV-coinfected persons, found an increased rate of liver-related deaths per year of ART in multivariable analyses also adjusted for latest CD4 cell counts [1], and the EuroSIDA observational cohort showed similar results [6].

The role of ART in liver-related mortality in patients without chronic viral hepatitis is less well defined. In the Swiss HIV Cohort Study (SHCS), elevated ALT (reported as adverse events to antiretrovirals) was associated with a higher mortality, independent of chronic hepatitis virus co-infections [7]. In contrast, mortality was not increased in participants with chronic ALT elevation and without viral hepatitis in another SHCS analysis, but the observation period was shorter and the patient number smaller [8]. Recently, new hepatic syndromes related to ART have emerged in HIV-infected persons. Non-cirrhotic portal hypertension, a potentially life-threatening liver disease, has been linked to didanosine use [9, 10]. Furthermore, steatosis and steatohepatitis are common in HIV-positive persons with and without chronic viral hepatitis [11, 12], and are associated with advanced liver fibrosis and cirrhosis [13]; ART as a risk factor has been discussed.

The aims of this study were (i) to assess liver-related mortality in HIV-positive persons without chronic viral hepatitis in the D:A:D cohort, and (ii) to provide comprehensive clinical details of these events. The role of ART and death was of particular interest.

## **METHODS**

### **Study design**

The D:A:D Study, founded in 1999, is a prospective observational study of 11 previously established cohorts as described in detail [14]. Currently, 49,737 HIV-positive individuals (33,308 from the original two recruitments with an additional 16,429 newly included in the cohort from 2009) are followed at 212 clinics in Europe, the United States, and Australia. The primary end point was myocardial infarction with other endpoints (including deaths) as secondary endpoints.

### **Data collection**

All participants were under active follow-up in their individual cohorts at the time of enrollment in the D:A:D study. At enrollment and at least every 8 months thereafter, standardized data collection forms are completed, including sociodemographic, clinical, laboratory, and treatment information. Data on HBV and HCV antibody status and hepatitis viral load assessments, if available, have been collected since January 2004. Previously collected HBV or HCV results by the participating cohorts were included. Information on causes of death have been prospectively collected using the Cause of Death (CoDe) in HIV protocol which is specifically designed for classifying causes of death in HIV-positive persons [15].

For the present analysis, deaths were classified as liver-related if the underlying cause was recorded as liver failure, regardless of the etiology. Other categories were AIDS, cardiovascular disease (CVD), non-AIDS malignancy (excluding AIDS-defining and hepatitis virus-associated malignancies), and other/unknown.

In all persons with liver-related death and negative HCV or HBV status the clinical charts were retrospectively reviewed by local investigators of participating institutions using a structured questionnaire. This chart review ascertained that inclusion criteria were met and provided additional information on the cause of liver-related death (including severe alcohol use, nonalcoholic fatty liver disease, medical treatment, non-cirrhotic portal hypertension, other disorders), liver-related symptoms, laboratory and histology results, and interventions, including liver transplantation. In unclear circumstances of liver-related death a brief narrative was given.

### **Definitions**

HCV infection was defined as present in persons who were sero-positive for HCV or who had test results positive for HCV RNA. HBV infection was defined as present in persons who were positive for hepatitis B surface antigen or hepatitis B e antigen or hepatitis B core antibodies or who had detectable HBV DNA during the study period. Thus, patients with chronic and previous HCV infections and chronic, active and previous HBV infections were excluded. Patients with unknown HBV or HCV status were also excluded. Severe alcohol use was defined according to the WHO definition as alcohol consumption in female >40g/d and in male >60g/d.

### **Statistical analyses**

All D:A:D study participants with negative HCV and HBV status were included.

Participants were followed from the date of entry into the D:A:D study until the date of death, the date of loss to follow-up (six months after the patient's last clinic visit), or the end of study follow-up (1st February 2010), whichever occurred first. The incidence of liver-related deaths was defined as the number of such deaths divided by the total

person-years of follow-up. HCV or HBV-negative participants with liver-related death were compared to participants without chronic viral hepatitis who died from causes that were not liver-related using data at baseline and data from the last clinic visit before death. P values were calculated using Fisher's exact tests and Mann-Whitney U tests, as appropriate. Due to the small number of endpoints multivariable analyses were not feasible.

Analyses were performed using SAS Version 9.1.

## RESULTS

### Baseline characteristics

Of 49,737 participants followed between 1 December 1999 and 1 February 2010, 19,618 (40%) were HCV or HBV positive at baseline, or during follow-up, and 2506 (5%) had unknown HCV or HBV status. 4703 (9%) participants were excluded because they belonged to cohorts not responding to the requested information for this study. Thus, 22,910 (46%) HCV and HBV negative participants who were followed for 114,478 patient-years, were included in these analyses (see Figure 1). Over the years, the percentage of patients with documentation gaps of more than 1 year remained low and varied between 3 and 6 percent. The baseline characteristics of the study participants are shown in Table 1.

A total of 1059 (4.6%) of the patients died; 12 (0.05%) were liver-related. Thus, the incidence of liver-related deaths in persons not co-infected with HCV or HBV was 0.10 per 1000 person-years (95% CI 0.05, 0.18).



### **Description of patients who died from liver disease**

Clinical data are summarized in Table 2: Five participants died due to ART toxicity. Of these, two patients experienced acute liver failure with lactic acidosis on regimens including didanosine and stavudine, with one patient also receiving metformin. A third patient developed fatal liver failure because of a hypersensitivity reaction to nevirapine; and two patients died of non-cirrhotic portal hypertension; both had been exposed to didanosine. The rate of ART-related death in treatment experienced individuals was 0.04 (95% confidence intervals 0.01, 0.10) with 5 events over 1000 person-years. Seven of the patients with liver-related deaths died due to severe alcohol use, including one patient with an additional diagnosis of hemochromatosis.

Liver biopsies were performed only in two patients and autopsy in one, confirming the diagnosis of alcoholic liver disease, respectively showing histological findings consistent with non-cirrhotic portal hypertension [10, 16]. No patient was treated with transjugular intrahepatic portal systemic shunting and none received a liver transplant.

### **Comparison of patients with liver-related death with patients without liver-related death**

Participants who died from all causes compared to patients who remained alive were more often male, and were older. Their first HIV diagnosis was earlier, their nadir and baseline CD4 cell counts were lower, maximum HIV-1 RNA levels higher, and more frequently had a history of previous clinical AIDS (data not shown).

Patients with liver-related death compared to patients who died from other causes (AIDS 376 [35.9%], CVD 116 [11.1%], non-AIDS malignancies 149 [14.2%], other causes 315 [30.1%], unknown causes 91 [8.7%]), were significantly longer exposed to ART at

baseline. Time of first HIV diagnosis was earlier, and enrollment in the D:A:D study was earlier, probably reflecting longer duration of HIV infection (Table 3).

## DISCUSSION

In this large prospective cohort of 22,910 HIV-positive participants without hepatitis co-infection, followed for 114,478 patient-years, the incidence of liver-related deaths was very low at 0.10 per 1000 patient-years. Among the 12 persons who died from liver-related causes, seven died because of alcohol use, and five most probably as a consequence of ART-related hepatotoxicity.

Liver-related mortality in the large population-based NHANES III study in the United states, in HCV antibody negative adults was 0.16 (95% CI, 0.10-0.25) per 1000 person years and thus very similar to our findings of 0.10 (0.05-0.18) among HIV positive individuals without HCV or HBV. In persons with chronic HCV infection, however, mortality in the NHANES III study was 4.4 (1.5-12.9) per 1000 person years [17].

In HIV-positive persons without HCV or HBV-coinfection, limited data are available on liver-related mortality. In the French Mortavic study 48 of 287 deaths (17%) in HIV-positive individuals in 2005 were related to end-stage liver disease of which 94% were attributable to chronic viral hepatitis. Severe alcohol consumption was reported in nearly half of the patients, and only three of 48 persons were HCV/HBV-negative [3]. In a recent collaborative analysis of 13 HIV cohorts, 113 of 1876 deaths (7%) were assigned to liver diseases. In 50 patients (44%), hepatitis viruses were not the cause of liver-related death. However, information on the proportion of patients with positive or unknown HCV/HBV sero-status was missing [18]. A previous analysis of the D:A:D study group found 341 of 2482 deaths (14%) to be liver-related; 56 patients (2.3%) with liver failure had no documentation of chronic viral hepatitis [4]. However, our current re-

investigation showed that chronic hepatitis virus infection was frequent in the group without HCV or HBV documentation.

We found that non-cirrhotic portal hypertension was the cause for only two liver-related deaths. In the last years, several case series and case reports on the disease have been published [10, 16, 19-22]. The pathogenesis is multi-factorial with didanosine exposure as an important risk factor. Patients present with esophageal varices, ascites, splenomegaly, portal vein thrombosis, variceal hemorrhage, or liver failure, as severe and life-threatening complications. Mortality in advanced stages is high [10].

Fortunately, current data indicate that it is indeed a rare disease with a lower mortality than previously suspected. We found two liver-related deaths attributable to severe hyperlactataemia. In both cases, regimens included stavudine and didanosine. Exposure to nucleoside reverse transcriptase inhibitors (NRTI), particularly to the dideoxynucleosides didanosine, stavudine and zalcitabine, is associated with the inhibition of mitochondrial DNA  $\gamma$ -polymerase leading to severe hyperlactataemia.

Lactic acidosis is rarely observed, but its mortality rate is high [23, 24], which is the reason that these drugs are no longer recommended. Non-nucleoside reverse transcriptase inhibitors (NNRTI), especially nevirapine, are associated with an increased risk of acute hepatotoxicity, typically due to hypersensitivity reactions. In line with our study findings, such adverse events are rare [25, 26].

We expected that liver-related deaths in persons not co-infected with hepatitis viruses were frequently due to severe alcohol consumption. Among HIV-positive persons, the reported prevalence of severe alcohol use ranges from 2.8 to 35% - depending on the observed population [27-30]. However, we found a low rate of deaths due to alcoholic liver disease, probably explained by the exclusion of many at-risk patients such as injecting drug users. This patient group who is at risk for multiple substance

dependence syndrome, including alcohol [30], had to almost completely be excluded from analyses because of chronic viral hepatitis.

In agreement with other investigations, older age, male gender, lower CD4 cell counts, high HIV-1 viral load, and previous clinical AIDS, were associated with death from all causes [18, 31]. We found that patients with liver-related death were longer exposed to ART and longer known to be HIV-infected, both of which might indicate a longer exposure to older and more hepatotoxic antiretrovirals, also in patients with alcoholic liver disease, in whom the cause of death might have been multi-factorial. But this remains speculative because of the low number of endpoints.

The strength of this study is its large size and the long-term prospective observation. Furthermore, the endpoint, liver-related cause of death, was prospectively collected and centrally adjudicated, using the CoDe system. Limitations are that multivariable analyses to identify associated risk factors were not possible because of the rare occurrence of endpoints under investigation; information on severe alcohol use was available only in case patients; and liver-related deaths were retrospectively reevaluated. We cannot rule out some underreporting of liver-related deaths. First, liver-related deaths might be difficult to capture because of multiple potential contributing factors (e.g. sepsis or renal dysfunction). Central adjudication by several experienced clinicians, however, should have minimized such misclassifications. Second, some patients may have experienced liver-related death after being lost to follow-up, a scenario which might be more common for patients with alcoholic liver disease. However, as patients totally lost from HIV care are unlikely to be on ART, these missed events are unlikely to contribute to rates of ART-related liver mortality. Furthermore, as follow-up on such patients is right-censored on the date of loss-to-follow-up, our rate estimates should not be substantially biased by the exclusion of these events. Finally, given the very small number of events

which limited a multivariable analysis of predictors of these liver-related deaths, it was not possible to perform a formal competing risks analysis to take account of individuals who died of other causes prior to the clinical manifestation of liver disease.

In conclusion, this is the first large study assessing liver-related deaths in HCV or HBV sero-negative patients. The incidence of liver-related deaths unrelated to chronic viral hepatitis, in particular life-threatening hepatotoxic side effects due to antiretrovirals, was very low and comparable to the general HCV-negative population in the United States. This is good news in times in which HIV-infection has evolved into a chronic disease, lifelong ART remains a necessity, earlier therapy for all HIV-positive persons is a matter of debate, and more co-medication - potentially leading to drug-drug interactions and hepatotoxicity - will be necessary in this aging and multi-morbid person group. Therefore, ongoing monitoring of liver-related mortality and its contributors in HIV-positive persons will remain important.

## ACKNOWLEDGMENTS

### D:A:D Participating Cohorts

Aquitaine	CPCRA	NICE Cohort
France	USA	France
ATHENA	EuroSIDA	SHCS
The Netherlands	Europe	Switzerland
AHOD	HIV-BIVUS	St.Pierre Brussels Cohort
Australia	Sweden	Belgium
BASS	The ICONA Foundation	
Spain	Italy	

**D:A:D Steering Committee:** Names marked with \*, Chair with #

Members of the D:A:D SC from the Oversight Committee: S. Collins, N. Shortman, D.

Butcher, R. Rode W. Powderly;

**D:A:D Central Coordination:** S.W. Worm, C.A. Sabin\*, D. Kamara, L. Ryom, M. Ellefson, C. Smith, J. Tverland, J. Nielsen, J.D. Lundgren#;

**D:A:D data managers:** R. Salbøl Brandt (coordinator), M. Rickenbach, L. Fanti, E. Krum, M. Hillebregt, S. Geffard, A. Sundström, M. Delforge, E. Fontas, F. Torres, H. McManus, S. Wright, J. Kjær.

**Verification of Endpoints:** A. Sjøl (CVD primary endpoint), P. Meidahl (oncology, new endpoint), J. Helweg-Larsen (hematology, new endpoint), J. Schmidt Iversen (nephrology, new endpoint)

**The members of the 11 Cohorts are as follows:**

**ATHENA** (AIDS Therapy Evaluation Project Netherlands):

**Central coordination:** F. de Wolf, S. Zaheri, M Hillebregt L.Gras;

**Participating physicians** (\*Site coordinating physicians): **Academisch Medisch**

**Centrum bij de Universiteit van Amsterdam, Amsterdam:** J.M. Prins\*, T.W. Kuijpers, H.J. Scherpbier, K. Boer, J.T.M. van der Meer, F.W.M.N. Wit, M.H. Godfried, P. Reiss, T. van der Poll, F.J.B. Nellen, J.M.A. Lange, S.E. Geerlings, M. van Vugt, S.M.E. Vrouwenraets, D.

Pajkrt, M. van der Valk. **Academisch Ziekenhuis Maastricht, Maastricht:** G. Schreij\*, S. Lowe, A. Oude Lashof. **Catharina-ziekenhuis, Eindhoven:** M.J.H. Pronk\*, B. Bravenboer.

**Erasmus Medisch Centrum, Rotterdam:** M.E. van der Ende\*, T.E.M.S. de Vries-Sluijs, C.A.M. Schurink, M. van der Feltz, J.L. Nouwen, L.B.S. Gelinck, A. Verbon, B.J.A. Rijnders, L. Slobbe. **Erasmus Medisch Centrum–Sophia, Rotterdam:** N.G. Hartwig, G.J.A. Driessen.

**Flevoziekenhuis, Almere:** J. Branger\*. **HagaZiekenhuis, Den Haag:** R.H. Kauffmann\*, E.F. Schippers. **Isala Klinieken, Zwolle:** P.H.P. Groeneveld\*, M.A. Alleman, J.W.

Bouwhuis. **Kennemer Gasthuis:** R.W. ten Kate\*, R. Soetekouw. **Leids Universitair**

**Medisch Centrum, Leiden:** F.P. Kroon\*, P.J. van den Broek, J.T. van Dissel, S.M. Arend, C. van Nieuwkoop, M.G.J. de Boer, H. Jolink. **Maasstadziekenhuis, Rotterdam:** J.G. den Hollander\*, K. Pogany. **Medisch Centrum Alkmaar, Alkmaar:** G. van Twillert\*, W.

Kortmann. **Medisch Centrum Haaglanden, Den Haag:** R. Vriesendorp\*, E.M.S. Leyten.

**Medisch Spectrum Twente, Enschede:** C.H.H. ten Napel\*, G.J. Kootstra. **Onze Lieve**

**Vrouwe Gasthuis, Amsterdam:** K. Brinkman\*, W.L. Blok, P.H.J. Frissen, W.E.M.

Schouten, G.E.L. van den Berk. **Sint Elisabeth Ziekenhuis, Tilburg:** J.R. Juttman\*,

M.E.E. van Kasteren, A.E. Brouwer. **Sint Lucas Andreas Ziekenhuis, Amsterdam:** J.

Veenstra\*, K.D. Lettinga. **Slotervaartziekenhuis, Amsterdam:** J.W. Mulder\*, E.C.M. van

Gorp, P.M. Smit, S. Weijer. **Stichting Medisch Centrum Jan van Goyen, Amsterdam:** A.

van Eeden\*, D.W.M. Verhagen\*. **Universitair Medisch Centrum Groningen,**

**Groningen:** H.G. Sprenger\*, R. Doedens, E.H. Scholvinck, S. van Assen, C.J. Stek.

**Universitair Medisch Centrum Sint Radboud, Nijmegen:** P.P. Koopmans\*, R. de Groot, M. Keuter, A.J.A.M. van der Ven, H.J.M. ter Hofstede, M. van der Flier, A.M. Brouwer, A.S.M.

Dofferhoff. **Universitair Medisch Centrum Utrecht, Utrecht:** A.I.M. Hoepelman\*, T. Mudrikova, M.M.E. Schneider, C.A.J.J. Jaspers, P.M. Ellerbroek, E.J.G. Peters, L.J.

Maarschalk-Ellerbroek, J.J. Oosterheert, J.E. Arends, M.W.M. Wassenberg, J.C.H. van der Hilst. **Vrije Universiteit Amsterdam, Amsterdam:** S.A. Danner\*, M.A. van Agtmael, J. de Vocht, R.M. Perenboom, F.A.P. Claessen, W.F.W. Bierman, E.V. de Jong, E.A. bij de Vaate.

**Wilhelmina Kinderziekenhuis, Utrecht:** S.P.M. Geelen, T.F.W. Wolfs. **Ziekenhuis**

**Rijnstate, Arnhem:** C. Richter\*, J.P. van der Berg, E.H. Gisolf. **Ziekenhuis Walcheren,**

**Vlissingen:** M. van den Berge\*, A. Stegeman. **Medisch Centrum Leeuwarden,**

**Leeuwarden:** D.P.F. van Houte\*, M.B. Polée, M.G.A. van Vonderen. **Sint Elisabeth**

**Hospitaal, Willemstad - Curaçao:** C. Winkel, A.J. Duits.

**Aquitaine Cohort (France)**

**Composition of the GECSA: Coordination:** F. Dabis. **Epidemiology and Methodology:**

M. Bruyand, G. Chêne, F. Dabis, S. Lawson-Ayayi, R. Thiébaut. **Infectious Diseases and**

**Internal Medicine:** F. Bonnal, F. Bonnet, N. Bernard, L. Caunègre, C. Cazanave, J.

Ceccaldi, D. Chambon, I. Chossat, FA. Dauchy, S. De Witte, M. Dupon, P. Duffau, H.

Dutronc, S. Farbos, V. Gaborieau, MC. Gemain, Y. Gerard, C. Greib, M. Hessamfar, D.

Lacoste, P. Lataste, S. Lafarie, E. Lazaro, D. Malvy, JP. Meraud, P. Mercié, E. Monlun, P.

Morlat, D. Neau, A. Ochoa, JL. Pellegrin, T. Pistone, JM. Ragnaud, MC. Receveur, S.

Tchamgoué, MA. Vandenhende, JF. Viallard. **Immunology:** JF. Moreau, I. Pellegrin.

**Virology:** H. Fleury, ME. Lafon, B. Masquelier, P. Trimoulet. **Pharmacology:** D. Breilh.

**Drug monitoring:** F. Haramburu, G. Miremont-Salamé. **Data collection and**

**processing:** MJ. Blaizeau, M. Decoin, J. Delaune, S. Delveaux, C. D'Ivernois, C. Hanapier, O.



Leleux, B. Uwamaliya-Nziyumvira, X Sicard. **Computing and Statistical analysis:** S. Geffard, G. Palmer, D. Touchard. **Scientific committee:** F. Bonnet, M. Dupon, P. Mercié, P. Morlat, JL. Pellegrin, JM. Ragnaud, F. Dabis.

**AHOD** (Australian HIV Observational Database, Australia):

**Central coordination:** M. Law <sup>¶</sup>, K. Petoumenos, H. McManus, S. Wright, C. Bendall (Sydney, New South Wales);

**Participating physicians** (city, state): R. Moore, S. Edwards, J. Hoy, K. Watson, N. Roth, J. Nicholson (Melbourne, Victoria); M Bloch, T. Franic, D. Baker, R. Vale, A. Carr, D. Cooper (Sydney, New South Wales); J. Chuah, M. Ngieng (Gold Coast, Queensland), D. Nolan, J. Skett (Perth, Western Australia).

**BASS** (Spain):

**Central coordination:** G. Calvo\*, F. Torres, S. Mateu (Barcelona);

**Participating physicians** (city): P. Domingo, M.A. Sambeat, J. Gatell, E. Del Cacho, J. Cadafalch, M. Fuster (Barcelona); C. Codina, G. Sirera, A. Vaqué (Badalona).

**The Brussels St Pierre Cohort** (Belgium): Coordination: S. De Wit<sup>¶</sup>, N. Clumeck, M. Delforge, C. Necsoi. Participating physicians: N. Clumeck, S. De Wit<sup>¶</sup>, AF Gennotte, M. Gerard, K. Kabeya, D. Konopnicki, A. Libois, C. Martin, M.C. Payen, P. Semaille, Y. Van Laethem.

**CPCRA** (USA):

**Central coordination:** J. Neaton, G. Bartsch, W.M. El-Sadr\*, E. Krum, G. Thompson, D. Wentworth;

**Participating physicians** (city, state): R. Luskin-Hawk (Chicago, Illinois); E. Telzak (Bronx, New York); W.M. El-Sadr (Harlem, New York); D.I. Abrams (San Francisco,

California); D. Cohn (Denver, Colorado); N. Markowitz (Detroit, Michigan); R. Arduino (Houston, Texas); D. Mushatt (New Orleans, Louisiana); G. Friedland (New Haven, Connecticut); G. Perez (Newark, New Jersey); E. Tedaldi (Philadelphia, Pennsylvania); E. Fisher (Richmond, Virginia); F. Gordin (Washington, DC); L.R. Crane (Detroit, Michigan); J. Sampson (Portland, Oregon); J. Baxter (Camden, New Jersey).

**EuroSIDA (multinational )**

**Coordinating Centre:** J Lundgren, O Kirk, A Mocroft, A Cozzi-Lepri, D Grint, M Ellefson, D Podlekareva, J Kjær, L Peters, J Reekie, J Kowalska, J Tverland, A H Fischer, J Nielsen

**Participating countries and physicians Argentina:** (M Losso), C Elias, Hospital JM Ramos Mejia, Buenos Aires.

**Austria:** (N Vetter), Pulmologisches Zentrum der Stadt Wien, Vienna; R Zangerle, Medical University Innsbruck, Innsbruck.

**Belarus:** (I Karpov), A Vassilenko, Belarus State Medical University, Minsk, VM Mitsura, Gomel State Medical University, Gomel; O Suetnov, Regional AIDS Centre, Svetlogorsk.

**Belgium:** (N Clumeck), S De Wit, M Delforge, Saint-Pierre Hospital, Brussels; R Colebunders, Institute of Tropical Medicine, Antwerp; L Vandekerckhove, University Ziekenhuis Gent, Gent.

**Bosnia-Herzegovina:** (V Hadziosmanovic), Klinicki Centar Univerziteta Sarajevo, Sarajevo.

**Bulgaria:** (K Kostov), Infectious Diseases Hospital, Sofia.

**Croatia:** (J Begovac), University Hospital of Infectious Diseases, Zagreb.

**Czech Republic:** (L Machala), D Jilich, Faculty Hospital Bulovka, Prague; D Sedlacek, Charles University Hospital, Plzen.

**Denmark:** (J Nielsen), G Kronborg, T Benfield, M Larsen, Hvidovre Hospital, Copenhagen; J Gerstoft, T Katzenstein, A-B E Hansen, P Skinhøj, Rigshospitalet, Copenhagen; C

Pedersen, Odense University Hospital, Odense; L Ostergaard, Skejby Hospital, Aarhus.

**Estonia:** (K Zilmer), West-Tallinn Central Hospital, Tallinn; Jelena Smidt, Nakkusosakond Sisekliinik, Kohtla-Järve.

**Finland:** (M Ristola), Helsinki University Central Hospital, Helsinki.

**France:** (C Katlama), Hôpital de la Pitié-Salpêtrière, Paris; J-P Viard, Hôpital Necker-Enfants Malades, Paris; P-M Girard, Hospital Saint-Antoine, Paris; JM Livrozet, Hôpital Edouard Herriot, Lyon; P Vanhems, University Claude Bernard, Lyon; C Pradier, Hôpital de l'Archet, Nice; F Dabis, D Neau, Unité INSERM, Bordeaux.

**Germany:** (J Rockstroh), Universitäts Klinik Bonn; R Schmidt, Medizinische Hochschule Hannover; J van Lunzen, O Degen, University Medical Center Hamburg-Eppendorf, Infectious Diseases Unit, Hamburg; HJ Stellbrink, IPM Study Center, Hamburg; S Staszewski, JW Goethe University Hospital, Frankfurt; J Bogner, Medizinische Poliklinik, Munich; G. Fätkenheuer, Universität Köln, Cologne.

**Greece:** (J Kosmidis), P Gargalianos, G Xylomenos, J Perdios, Athens General Hospital; G Panos, A Filandras, E Karabatsaki, 1st IKA Hospital; H Sambatakou, Ippokration Genereal Hospital, Athens.

**Hungary:** (D Banhegyi), Szent László Hospital, Budapest.

**Ireland:** (F Mulcahy), St. James's Hospital, Dublin.

**Israel:** (I Yust), D Turner, M Burke, Ichilov Hospital, Tel Aviv; S Pollack, G Hassoun, Rambam Medical Center, Haifa; S Maayan, Hadassah University Hospital, Jerusalem.

**Italy:** (S Vella), Istituto Superiore di Sanità, Rome; R Esposito, I Mazeu, C Mussini, Università Modena, Modena; C Arici, Ospedale Riuniti, Bergamo; R Pristera, Ospedale Generale Regionale, Bolzano; F Mazzotta, A Gabbuti, Ospedale S Maria Annunziata, Firenze; V Vullo, M Lichtner, University di Roma la Sapienza, Rome; A Chirianni, E Montesarchio, M Gargiulo, Presidio Ospedaliero AD Cotugno, Monaldi Hospital, Napoli; G

Antonucci, A Testa, P Narciso, C Vlassi, M Zaccarelli, Istituto Nazionale Malattie Infettive Lazzaro Spallanzani, Rome; A Lazzarin, A Castagna, N Gianotti, Ospedale San Raffaele, Milan; M Galli, A Ridolfo, Osp. L. Sacco, Milan; A d'Arminio Monforte, Istituto Di Clinica Malattie Infettive e Tropicale, Milan.

**Latvia:** (B Rozentale), I Zeltina, Infectology Centre of Latvia, Riga.

**Lithuania:** (S Chaplinskas), Lithuanian AIDS Centre, Vilnius.

**Luxembourg:** (R Hemmer), T Staub, Centre Hospitalier, Luxembourg.

**Netherlands:** (P Reiss), Academisch Medisch Centrum bij de Universiteit van Amsterdam, Amsterdam.

**Norway:** (V Ormaasen), A Maeland, J Bruun, Ullevål Hospital, Oslo.

**Poland:** (B Knysz) J Gasiorowski, Medical University, Wroclaw; A Horban, E Bakowska, Centrum Diagnostyki i Terapii AIDS, Warsaw; A Grzeszczuk, R Flisiak, Medical University, Bialystok; A Boron-Kaczmarek, M Pynka, M Parczewski, Medical University, Szczecin; M Beniowski, E Mularska, Ośrodek Diagnostyki i Terapii AIDS, Chorzow; H Trocha, Medical University, Gdansk; E Jablonowska, E Malolepsza, K Wojcik, Wojewodzki Szpital Specjalistyczny, Lodz.

**Portugal:** (F Antunes), M Doroana, L Caldeira, Hospital Santa Maria, Lisbon; K Mansinho, Hospital de Egas Moniz, Lisbon; F Maltez, Hospital Curry Cabral, Lisbon.

**Romania:** (D Duiculescu), Spitalul de Boli Infectioase si Tropicale: Dr. Victor Babes, Bucarest.

**Russia:** (A Rakhmanova), Medical Academy Botkin Hospital, St Petersburg; N Zakharova, St Petersburg AIDS Centre, St Peterburg; S Buzunova, Novgorod Centre for AIDS, Novgorod.

**Serbia:** (D Jevtovic), The Institute for Infectious and Tropical Diseases, Belgrade.

**Slovakia:** (M Mokráš), D Staneková, Dérer Hospital, Bratislava.

**Slovenia:** (J Tomazic), University Clinical Centre Ljubljana, Ljubljana.

**Spain:** (J González-Lahoz), V Soriano, P Labarga, J Medrano, Hospital Carlos III, Madrid; S Moreno, JM Rodriguez, Hospital Ramon y Cajal, Madrid; B Clotet, A Jou, R Paredes, C Tural, J Puig, I Bravo, Hospital Germans Trias i Pujol, Badalona; JM Gatell, JM Miró, Hospital Clinic i Provincial, Barcelona; P Domingo, M Gutierrez, G Mateo, MA Sambeat, Hospital Sant Pau, Barcelona.

**Sweden:** (A Karlsson), Venhaelsan-Sodersjukhuset, Stockholm; L Flamholc, Malmö University Hospital, Malmö.

**Switzerland:** (B Ledergerber), R Weber, University Hospital, Zürich; P Francioli, M Cavassini, Centre Hospitalier Universitaire Vaudois, Lausanne; B Hirschel, E Boffi, Hospital Cantonal Universitaire de Geneve, Geneve; H Furrer, Inselspital Bern, Bern; M Battegay, L Elzi, University Hospital Basel.

**Ukraine:** (E Kravchenko), N Chentsova, Kiev Centre for AIDS, Kiev; V Frolov, G Kutsyna, Luhansk State Medical University, Luhansk; S Servitskiy, Odessa Region AIDS Center, Odessa; M Krasnov, Kharkov State Medical University, Kharkov.

**United Kingdom:** (S Barton), St. Stephen's Clinic, Chelsea and Westminster Hospital, London; AM Johnson, D Mercey, Royal Free and University College London Medical School, London (University College Campus); A Phillips, MA Johnson, A Mocroft, Royal Free and University College Medical School, London (Royal Free Campus); M Murphy, Medical College of Saint Bartholomew's Hospital, London; J Weber, G Scullard, Imperial College School of Medicine at St. Mary's, London; M Fisher, Royal Sussex County Hospital, Brighton; C Leen, Western General Hospital, Edinburgh.

**HivBivus** (Sweden):

**Central coordination:** L. Morfeldt\*, G. Thulin, A. Sundström.

**Participating physicians (city):** B. Åkerlund (Huddinge); K. Koppel, A. Karlsson (Stockholm); L. Flamholz, C. Håkangård (Malmö).

**The ICONA Foundation (Italy):**

**Governing Body:** M. Moroni (Chair), A. Antinori, G. Carosi, R. Cauda, F. Chiodo, A. d'Arminio Monforte, G Di Perri, M Galli, F. Ghinelli, R Iardino, G. Ippolito, A. Lazzarin, F. Mazzotta, R. Panebianco, G. Pastore, C.F. Perno

**Scientific Secretary:** A. d'Arminio Monforte

**Steering Committee:** A. Ammassari, A. Antinori, C. Balotta, P. Bonfanti, M.R. Capobianchi, A. Castagna, F. Ceccherini-Silberstein, A. Cozzi-Lepri, A. d'Arminio Monforte, A. De Luca, C. Gervasoni, E. Girardi, S. Lo Caputo, F Maggiolo, R. Murri, C. Mussini, M. Puoti, C. Torti

**Statistical and monitoring team:** A Cozzi-Lepri, I Fanti, T Formenti

**Participating physicians and centres:** M. Montroni, A. Giacometti, A Costantini, A. Riva (Ancona); U. Tirelli, F. Martellotta (Aviano-PN); G. Pastore, N. Ladisa, (Bari); F. Suter, F. Maggiolo (Bergamo); F. Chiodo, G. Verucchi, C. Fiorini (Bologna); G. Carosi, G. Cristini, C. Torti, C. Minardi, D. Bertelli (Brescia); T. Quirino, C Abeli (Busto Arsizio); P.E. Manconi, P. Piano (Cagliari); J Vecchiet, M. Farenga (Chieti); G Carnevale, S Lorenzotti (Cremona); F. Ghinelli, L. Sighinolfi (Ferrara); F. Leoncini, F. Mazzotta, M. Pozzi, S. Lo Caputo (Firenze); G. Pagano, G. Cassola, G Viscoli, A. Alessandrini, R. Piscopo, G Mazzarello (Genova); F. Soscia, L. Tacconi (Latina); A. Orani, R. Rossotto (Lecco); D Tommasi, P Congedo (Lecce); A. Chiodera, P. Castelli (Macerata); M Galli, A. Lazzarin, G. Rizzardini, I Schlacht, A. d'Arminio Monforte, AL Ridolfo, A Foschi, A Castagna, S Salpietro, S. Merli, S. Melzi, M.C. Moiola, P Cicconi, T Formenti (Milano); R. Esposito, C. Mussini (Modena); A Gori (Monza), N. Abrescia, A. Chirianni, CM Izzo, M. De Marco, R. Viglietti, E Manzillo (Napoli); C. Ferrari, P. Pizzaferrri (Parma); F Baldelli, G Camanni (Perugia); G. Magnani, M.A. Ursitti

(Reggio Emilia); M. Arlotti, P. Ortolani (Rimini); R. Cauda, M. Andreoni, A. Antinori, G. Antonucci, P. Narciso, V. Tozzi, V. Vullo, A. De Luca, M. Zaccarelli, R. Acinapura, P. De Longis, M.P. Trotta, M. Lichtner, F. Carletti, (Roma); M.S. Mura, G. Madeddu (Sassari); P. Caramello, G. Di Perri, G.C. Orofino, (Torino); E. Raise, F. Ebo (Venezia); G. Pellizzer, D. Buonfrate (Vicenza).

**Nice HIV Cohort** (France):

**Central coordination:** C. Pradier, E. Fontas, C. Caissotti.

**Participating physicians:** P. Dellamonica, E. Bernard, E. Cua, F. De Salvador-Guillouet, J. Durant, S. Ferrando, V. Mondain-Miton, A. Naqvi, I. Perbost, B. Prouvost-Keller, S. Pillet, P. Pugliese, V. Rahelinirina, P.M. Roger.

**Clinical research assistant:** K. Dollet

**SHCS** (Swiss HIV Cohort Study, Switzerland):

Barth J, Battegay M, Bernasconi E, Böni J, Bucher HC, Burton-Jeangros C, Calmy A, Cavassini M, Celleraï C, Dubs R, Egger M, Elzi L, Fehr J, Flepp M, Francioli P (President of the SHCS), Furrer H, Fux CA, Gorgievski M, Günthard H, Hasse B, Hirsch HH, Hirschel B, Hösli I, Kahlert C, Kaiser L, Keiser O, Kind C, Klimkait T, Kovari H, Ledergerber B, Martinetti G, Martinez de Tejada B, Müller N, Nadal D, Pantaleo G, Rauch A, Regenass S, Rickenbach M, Rudin C, Schmid P, Schultze D, Schöni-Affolter F, Schüpbach J, Speck R, Taffé P, Telenti A, Trkola A, Vernazza P, von Wyl V, Weber R\*, Yerly S.

**Financial acknowledgements:**

This work was supported by the Oversight Committee for The Evaluation of Metabolic Complications of HAART, a collaborative committee with representation from academic institutions, the European Agency for the valuation of Medicinal Products, the Food and Drug Administration, the patient community, and all pharmaceutical companies with

licensed anti-HIV drugs in the U.S. market: Abbott, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline, Merck, Pfizer, and Hoffman-LaRoche.

Supported by a grant (CURE/97-46486) from the Health Insurance Fund Council, Amstelveen, the Netherlands, to the AIDS Therapy Evaluation Project Netherlands (ATHENA); by a grant from the Agence Nationale de Recherches sur le SIDA (Action Coordonnée no.7, Cohortes), to the Aquitaine Cohort; The Australian HIV Observational Database (AHOD) is funded as part of the Asia Pacific HIV Observational Database, a program of The Foundation for AIDS Research, amfAR, and is supported in part by a grant from the U.S. National Institutes of Health's National Institute of Allergy and Infectious Diseases (NIAID) (Grant No. U01-AI069907) and by unconditional grants from Merck Sharp & Dohme; Gilead; Bristol-Myers Squibb; Boehringer Ingelheim; Roche; Pfizer; GlaxoSmithKline; Janssen-Cilag. The National Centre in HIV Epidemiology and Clinical Research is funded by The Australian Government Department of Health and Ageing, and is affiliated with the Faculty of Medicine, The University of New South Wales. The content of this publication is solely the responsibility of the authors and does not necessarily represent the official views of any of the institutions mentioned above;

by grants from the Fondo de Investigación Sanitaria (FIS 99/0887) and Fundación para la Investigación y la Prevención del SIDA en España (FIPSE 3171/00), to the Barcelona Antiretroviral Surveillance Study (BASS); by the National Institute of Allergy and Infectious Diseases, National Institutes of Health (grants 5U01AI042170-10 and 5U01AI046362-03), to the Terry Bein Community Programs for Clinical Research on AIDS (CPCRA); by grants from the BIOMED 1 (CT94-1637) and BIOMED 2 (CT97-2713) programs and the fifth framework program (QLK2-2000-00773) of the European Commission and grants from Bristol-Myers Squibb, GlaxoSmithKline, Boehringer Ingelheim, and Roche, to the EuroSIDA study; by unrestricted educational grants



of Abbott, Bristol-Myers Squibb, Gilead, GSK, Pfizer, Janssen-Cilag to the Italian Cohort Naive to Antiretrovirals (The ICONA Foundation); and by a grant from the Swiss National Science Foundation, to the Swiss HIV Cohort Study (SHCS). There are no other reported disclosures for this article.

## REFERENCES

1. Weber R, Sabin CA, Friis-Moller N, et al. Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. *Arch Intern Med*, **2006**; 166: 1632-41.
2. Lewden C, May T, Rosenthal E, et al. Changes in causes of death among adults infected by HIV between 2000 and 2005: The "Mortalite 2000 and 2005" surveys (ANRS EN19 and Mortavic). *J Acquir Immune Defic Syndr*, **2008**; 48: 590-8.
3. Rosenthal E, Salmon-Ceron D, Lewden C, et al. Liver-related deaths in HIV-infected patients between 1995 and 2005 in the French GERMIVIC Joint Study Group Network (Mortavic 2005 study in collaboration with the Mortalite 2005 survey, ANRS EN19). *HIV Med*, **2009**; 10: 282-9.
4. Smith C. Factors associated with specific causes of death amongst HIV-positive individuals in the D:A:D Study. *AIDS*, **2010**; 24: 1537-48.
5. Kovari H, Weber R. Influence of antiretroviral therapy on liver disease. *Curr Opin HIV AIDS*, **2011**; 6: 272-7.
6. Mocroft A, Soriano V, Rockstroh J, et al. Is there evidence for an increase in the death rate from liver-related disease in patients with HIV? *AIDS*, **2005**; 19: 2117-25.
7. Keiser O, Fellay J, Opravil M, et al. Adverse events to antiretrovirals in the Swiss HIV Cohort Study: effect on mortality and treatment modification. *Antivir Ther*, **2007**; 12: 1157-64.
8. Kovari H, Ledergerber B, Battegay M, et al. Incidence and risk factors for chronic elevation of alanine aminotransferase levels in HIV-infected persons without hepatitis b or c virus co-infection. *Clin Infect Dis*, **2010**; 50: 502-11.
9. Maida I, Nunez M, Rios MJ, et al. Severe liver disease associated with prolonged exposure to antiretroviral drugs. *J Acquir Immune Defic Syndr*, **2006**; 42: 177-82.
10. Kovari H, Ledergerber B, Peter U, et al. Association of noncirrhotic portal hypertension in HIV-infected persons and antiretroviral therapy with didanosine: a nested case-control study. *Clin Infect Dis*, **2009**; 49: 626-35.
11. McGovern BH, Ditelberg JS, Taylor LE, et al. Hepatic steatosis is associated with fibrosis, nucleoside analogue use, and hepatitis C virus genotype 3 infection in HIV-seropositive patients. *Clin Infect Dis*, **2006**; 43: 365-72.
12. Guaraldi G, Squillace N, Stentarelli C, et al. Nonalcoholic fatty liver disease in HIV-infected patients referred to a metabolic clinic: prevalence, characteristics, and predictors. *Clin Infect Dis*, **2008**; 47: 250-7.
13. Ingiliz P, Valantin MA, Duvivier C, et al. Liver damage underlying unexplained transaminase elevation in human immunodeficiency virus-1 mono-infected patients on antiretroviral therapy. *Hepatology*, **2009**; 49: 436-42.
14. Friis-Moller N, Sabin CA, Weber R, et al. Combination antiretroviral therapy and the risk of myocardial infarction. *N Engl J Med*, **2003**; 349: 1993-2003.
15. Kowalska JD, Friis-Moller N, Kirk O, et al. The Coding Causes of Death in HIV (CoDe) Project: initial results and evaluation of methodology. *Epidemiology*, **2011**; 22: 516-23.
16. Vispo E, Moreno A, Maida I, et al. Noncirrhotic portal hypertension in HIV-infected patients: unique clinical and pathological findings. *AIDS*, **2010**; 24: 1171-6.
17. El-Kamary SS, Jhaveri R, Shardell MD. All-cause, liver-related, and non-liver-related mortality among HCV-infected individuals in the general US population. *Clin Infect Dis*, **2011**; 53: 150-7.
18. Causes of death in HIV-1-infected patients treated with antiretroviral therapy, 1996-2006: collaborative analysis of 13 HIV cohort studies. *Clin Infect Dis*, **2010**; 50: 1387-96.
19. Mallet V, Blanchard P, Verkarre V, et al. Nodular regenerative hyperplasia is a new cause of chronic liver disease in HIV-infected patients. *Aids*, **2007**; 21: 187-92.
20. Schiano TD, Kotler DP, Ferran E, Fiel MI. Hepatoportal sclerosis as a cause of noncirrhotic portal hypertension in patients with HIV. *Am J Gastroenterol*, **2007**; 102: 2536-40.
21. Saifee S, Joelson D, Braude J, et al. Noncirrhotic portal hypertension in patients with human immunodeficiency virus-1 infection. *Clin Gastroenterol Hepatol*, **2008**; 6: 1167-9.
22. Chang PE, Miquel R, Blanco JL, et al. Idiopathic portal hypertension in patients with HIV infection treated with highly active antiretroviral therapy. *Am J Gastroenterol*, **2009**; 104: 1707-14.
23. Falco V, Rodriguez D, Ribera E, et al. Severe nucleoside-associated lactic acidosis in human immunodeficiency virus-infected patients: report of 12 cases and review of the literature. *Clin Infect Dis*, **2002**; 34: 838-46.
24. Arenas-Pinto A, Grant A, Bhaskaran K, et al. Risk factors for fatality in HIV-infected patients with dideoxynucleoside-induced severe hyperlactataemia or lactic acidosis. *Antivir Ther*, **2011**; 16: 219-26.

25. Sanne I, Mommeja-Marin H, Hinkle J, et al. Severe hepatotoxicity associated with nevirapine use in HIV-infected subjects. *J Infect Dis*, **2005**; 191: 825-9.
26. Chu KM, Boulle AM, Ford N, et al. Nevirapine-associated early hepatotoxicity: incidence, risk factors, and associated mortality in a primary care ART programme in South Africa. *PLoS One*, **2010**; 5: e9183.
27. Chander G, Lau B, Moore RD. Hazardous alcohol use: a risk factor for non-adherence and lack of suppression in HIV infection. *J Acquir Immune Defic Syndr*, **2006**; 43: 411-7.
28. Justice AC, Lasky E, McGinnis KA, et al. Medical disease and alcohol use among veterans with human immunodeficiency infection: A comparison of disease measurement strategies. *Med Care*, **2006**; 44: S52-60.
29. Samet JH, Cheng DM, Libman H, et al. Alcohol consumption and HIV disease progression. *J Acquir Immune Defic Syndr*, **2007**; 46: 194-9.
30. Conen A, Fehr J, Glass TR, et al. Self-reported alcohol consumption and its association with adherence and outcome of antiretroviral therapy in the Swiss HIV Cohort Study. *Antivir Ther*, **2009**; 14: 349-57.
31. Marin B, Thiebaut R, Bucher HC, et al. Non-AIDS-defining deaths and immunodeficiency in the era of combination antiretroviral therapy. *AIDS*, **2009**; 23: 1743-53.

**Table 1:** Characteristics of D:A:D study participants without HCV or HBV co-infection at study entry.

<b>Total of participants</b>	<b>n</b>	<b>22,910</b>
Male gender	n (%)	<b>16737 (73.1)</b>
Age (years)	median (IQR)	<b>38 (32, 46)</b>
Period of D:A:D cohort registration, n (%)	≤2002	<b>11896 (51.9)</b>
	2003-2006	<b>7060 (30.8)</b>
	2007-2009	<b>3954 (17.3)</b>
Duration of D:A:D cohort follow-up	median (IQR)	<b>4.9 (2.2, 8.3)</b>
Ethnicity, n (%)	white	<b>10827 (47.3)</b>
	black	<b>1762 (7.7)</b>
	other	<b>499 (2.2)</b>
	unknown	<b>9817 (42.9)</b>
Mode of HIV transmission, n (%)	heterosexual	<b>9472 (41.3)</b>
	homosexual	<b>11430 (49.9)</b>
	IDU	<b>404 (1.8)</b>
	other/unknown	<b>1604 (7.0)</b>
Year of first HIV diagnosis	median (IQR)	<b>1999 (1994, 2004)</b>
BMI (kg/m <sup>2</sup> ), n (%)	<18	<b>621 (2.7)</b>
	>18, <26	<b>13228 (57.7)</b>
	>26, <30	<b>2618 (11.4)</b>
	>30	<b>902 (3.9)</b>
	Unknown	<b>5541 (24.2)</b>
Diabetes mellitus	n (%)	<b>597 (2.6)</b>
Smoking status, n (%)	current	<b>7014 (30.6)</b>
	former	<b>4715 (20.6)</b>
	never	<b>6788 (29.6)</b>
	unknown	<b>4393 (19.2)</b>
CD4 cells/μL	median (IQR)	<b>410 (250, 595)</b>
	n (%) <200	<b>3837 (17.9)</b>
Previous clinical AIDS	n (%)	<b>5176 (22.6)</b>
Cumulative ART exposure (years)	median (IQR)	<b>0.9 (0.0, 3.5)</b>
Cumulative NRTI exposure (years)	median (IQR)	<b>0.8 (0.0, 3.5)</b>
Cumulative PI exposure (years)	median (IQR)	<b>0.0 (0.0, 2.1)</b>
Cumulative NNRTI exposure (years)	median (IQR)	<b>0.0 (0.0, 0.3)</b>
Treatment status, n (%)	naïve	<b>8724 (38.1)</b>
	interruption	<b>1072 (4.7)</b>
	on ART	<b>13114 (57.2)</b>

**Table 2:** Clinical description of HIV-positive patients without HCV or HBV infection and liver-related death.

Patient	Cause of death	Date of death	Clinical manifestations	Sex	Age at BL	First HIV diagnosis	CD4 cell count/ $\mu$ L		HIV RNA*		CDC stage C	Exposure to ART (years)		Comments
							BL	last	BL	last		BL	last	
1	Alcohol	2003	esophageal varices, ascites	M	55	1984	420	350	<50	5.37	yes	5.7	7.4	
2	Alcohol	2005	not reported	M	38	1988	322	137	<50	4.08	yes	6.9	11.9	
3	Alcohol	2005	splenomegaly	M	34	1991	174	236	3.45	<50	yes	6.3	11.7	Hemochromatosis
4	Alcohol	2001	ascites, encephalopathy, HCC	M	57	1991	640	350	<50	<50	yes	3.8	4.3	
5	Alcohol	2003	not reported	M	40	1986	297	242	4.20	5.00	no	8.5	10.9	
6	Alcohol	2007	splenomegaly, ascites	M	35	1995	375	311	3.40	4.11	no	4.4	8.6	
7	Alcohol	2004	splenomegaly, esophageal varices, variceal bleeding, ascites	F	34	2000	405	247	4.18	5.62	no	0	0	
8	NCPH	2000	splenomegaly, esophageal varices, ascites	M	56	1990	114	114	<50	1.70	no	8.0	8.4	NCPH, ddl
9	ART	2001	splenomegaly, encephalopathy	M	82	1994	437	437	1.94	1.99	no	5.6	6.1	Lactic acidosis: ddl, d4T
10	ART	2000	ascites	F	46	1993	1080	1080	<50	<50	yes	3.4	3.5	Hypersens: NVP
11	ART	2006	splenomegaly, esophageal varices, ascites, encephalopathy	M	44	1996	309	327	3.73	4.66	yes	5.4	9.1	Lactic acidosis: DDI, D4T, metformin
12	NCPH	2001	splenomegaly, esophageal varices, portal vein thrombosis	M	54	1993	175	339	3.63	3.48	no	5.5	6.6	NCPH, ddl

\* Log10 copies/ml or below 50 HIV RNA copies/ml


Abbreviations: ART, antiretroviral therapy. BL, baseline. ddl, didanosine. D4T, stavudine. EFV, efavirenz. F, female. HCC, hepatocellular carcinoma. Hypersens, hypersensitivity reaction. M, male. NCPH, non-cirrhotic portal hypertension. NVP, nevirapine.

**Table 3: Comparison of characteristics of HCV- and HBV-seronegative patients with liver-related death with HCV- and HBV-seronegative patients dying from other causes.**

		<b>Liver-related death</b>	<b>Death from other causes*</b>	<b>P value</b>
<b>No. of patients (%)</b>		12 (100)	1047 (100)	
Male gender	n (%)	10 (83.3)	876 (83.7)	1.00
Age (years)	median (IQR)	45 (36, 55)	47 (38, 57)	0.74
Year of first HIV diagnosis	median (IQR)	92 (89, 94)	95 (90, 00)	0.05
Date of D:A:D cohort registration,	<2002	12 (100.0)	793 (75.7)	0.15
	2003-2006	0	216 (20.6)	
	2007-2009	0	38 (3.6)	
<b>At baseline</b>				
Exposure to ART, years	median (IQR)	5.5 (4.1, 6.6)	2.8 (0.1, 5.2)	0.008
Treatment status, n(%)	naive	1 (8.3)	238 (22.7)	0.23
	interruption	0 (-)	84 (8.0)	
	on ART	11 (91.7)	725 (69.3)	
<b>At last visit</b>				
Nadir CD4 cells/ $\mu$ L	median (IQR)	97 (56, 171)	70 (16, 165)	0.50
Peak HIV-1 RNA (log10copies/ml)	median (IQR)	5.2 (4.9, 5.6)	5.3 (4.7, 5.8)	0.45
Previous clinical AIDS	n (%)	6 (50.0)	688 (65.7)	0.40
<b>Cumulative ART exposure</b>				
Any, years	median (IQR)	7.9 (5.2, 10.0)	5.6 (1.5, 8.9)	0.14
NRTIs, years	median (IQR)	7.9 (5.2, 10.0)	5.4 (1.5, 8.6)	0.11
NNRTIs, years	median (IQR)	0.9 (0.0, 1.6)	0.6 (0.0, 2.2)	0.98
PIs, years	median (IQR)	3.5 (0.2, 6.8)	2.7 (0.3, 5.1)	0.68
Current treatment status, n (%)	naive	1 (8.3)	66 (6.3)	0.75
	interruption	3 (25.0)	370 (35.3)	
	on ART	8 (66.7)	611 (58.4)	

\*Death from other causes, n (%): AIDS 376 (35.9), cardiovascular disease 116 (11.1), non-AIDS malignancies 149 (14.2), other causes 315 (30.1), unknown causes 91 (8.7).

**Abbreviations:** ART, antiretroviral therapy; NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor; PI, protease inhibitor.

**Figure 1:** Patient Flowchart

Abbreviations: FUP, follow-up; HBV, hepatitis B virus; HCV, hepatitis C virus.